Newco Idel Therapeutics GmbH has closed a €9 million (US$10.4 million) seed round to advance the development of a technology for delivery of cytotoxic drugs directly into the cytosol of tumor cells.
Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.
Endogenex Inc. has raised $50 million in an extension to its series C financing round to fund the completion of its pivotal Recet clinical study, which is evaluating the use of the company’s non-thermal pulsed electric field system for remodeling the duodenal tissue in adults with type 2 diabetes. The new capital will also be used to support the company's regulatory pathway toward U.S. FDA approval.
Biopharma and med-tech companies raising money in public or private financings, including: Amani, Karyopharm, Outlook, Research Alliance, Rybodyn, Sernova, Sol-Gel, Turn, Virchow.
Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.
Biopharma and med-tech companies raising money in public or private financings, including: Azitra, Bioxytran, Blue Water Acquisition, Bonus, Capsovision, Earendil, Hansa, Verily.
Laigo Bio BV has extended its seed round to €17 million (US$19.8 million), after making progress with translating its novel E3 ubiquitin ligase targeted protein degradation technology toward the clinic.
Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases.
RSS
